129 related articles for article (PubMed ID: 10674881)
1. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.
Robertson JF; Howell A; Buzdar A; von Euler M; Lee D
Breast Cancer Res Treat; 1999 Nov; 58(2):157-62. PubMed ID: 10674881
[TBL] [Abstract][Full Text] [Related]
2. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
Jonat W; Howell A; Blomqvist C; Eiermann W; Winblad G; Tyrrell C; Mauriac L; Roche H; Lundgren S; Hellmund R; Azab M
Eur J Cancer; 1996 Mar; 32A(3):404-12. PubMed ID: 8814682
[TBL] [Abstract][Full Text] [Related]
3. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
[TBL] [Abstract][Full Text] [Related]
4. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
[TBL] [Abstract][Full Text] [Related]
5. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
Buzdar AU; Jonat W; Howell A; Jones SE; Blomqvist CP; Vogel CL; Eiermann W; Wolter JM; Steinberg M; Webster A; Lee D
Cancer; 1998 Sep; 83(6):1142-52. PubMed ID: 9740079
[TBL] [Abstract][Full Text] [Related]
6. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
Wiseman LR; Adkins JC
Drugs Aging; 1998 Oct; 13(4):321-32. PubMed ID: 9805213
[TBL] [Abstract][Full Text] [Related]
7. Clinical overview of anastrozole--a new selective oral aromatase inhibitor.
Jonat W
Oncology; 1997; 54 Suppl 2():15-8. PubMed ID: 9394855
[TBL] [Abstract][Full Text] [Related]
8. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883
[TBL] [Abstract][Full Text] [Related]
9. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
10. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
11. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
Lønning PE
Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):12-5. PubMed ID: 9741783
[TBL] [Abstract][Full Text] [Related]
13. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
Nabholtz JM
Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer.
Sendur MA; Aksoy S; Zengin N; Altundag K
J BUON; 2013; 18(4):838-44. PubMed ID: 24344006
[TBL] [Abstract][Full Text] [Related]
15. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
[TBL] [Abstract][Full Text] [Related]
16. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
Bonneterre J; Buzdar A; Nabholtz JM; Robertson JF; Thürlimann B; von Euler M; Sahmoud T; Webster A; Steinberg M; ;
Cancer; 2001 Nov; 92(9):2247-58. PubMed ID: 11745278
[TBL] [Abstract][Full Text] [Related]
17. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
Polychronis A; Sinnett HD; Hadjiminas D; Singhal H; Mansi JL; Shivapatham D; Shousha S; Jiang J; Peston D; Barrett N; Vigushin D; Morrison K; Beresford E; Ali S; Slade MJ; Coombes RC
Lancet Oncol; 2005 Jun; 6(6):383-91. PubMed ID: 15925816
[TBL] [Abstract][Full Text] [Related]
18. ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer.
Buzdar AU; Jonat W; Howell A; Plourde PV
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):145-9. PubMed ID: 9365184
[TBL] [Abstract][Full Text] [Related]
19. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
20. A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
Howell A; Robertson JF; Vergote I
Breast Cancer Res Treat; 2003 Dec; 82(3):215-22. PubMed ID: 14703069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
